Trials / Unknown
UnknownNCT02529579
Safety and Efficacy Evaluation of iAPA-DC/CTL Combined Gemcitabine Therapy on Advanced Pancreatic Cancer
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 187 (estimated)
- Sponsor
- Changhai Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to evaluate the safety and efficacy of iAPA-DC/CTL combined gemcitabine therapy on advanced pancreatic cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | iAPA-DC/CTL adoptive cellular immunotherapy | twice DC cell infusion and CTL cell infusion for 6 times |
| DRUG | Gemcitabine | standard Gemcitabine therapy |
Timeline
- Start date
- 2015-06-01
- Primary completion
- 2018-12-01
- Completion
- 2019-12-01
- First posted
- 2015-08-20
- Last updated
- 2015-08-20
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02529579. Inclusion in this directory is not an endorsement.